|
PSA
0 – 2.5 ng/ml
|
|
Gleason Score
|
Pathology Risk
|
Clinical
Stage
|
|
T1c
|
T2a
|
T2b
|
T2c
|
|
2-4
|
Confined
to Prostate
|
95
|
89-99
|
91
|
79-98
|
88
|
79-97
|
86
|
71-97
|
|
Spread to Prostate Capsule
|
5
|
1-11
|
9
|
2-21
|
12
|
3-27
|
14
|
3-29
|
|
Spread to Seminal Vesicles
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
5-6
|
Confined
to Prostate
|
90
|
88-93
|
81
|
77-85
|
75
|
69-81
|
73
|
63-81
|
| |
Spread to Prostate Capsule
|
9
|
7-12
|
17
|
13-21
|
22
|
17-28
|
24
|
17-33
|
| |
Spread to Seminal Vesicles
|
0
|
0-1
|
1
|
0-2
|
2
|
0-3
|
1
|
0-4
|
| |
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-1
|
1
|
0-2
|
1
|
0-4
|
|
3+4=7
|
Confined
to Prostate
|
79
|
74-85
|
64
|
56-71
|
54
|
46-63
|
51
|
38-63
|
|
Spread to Prostate Capsule
|
17
|
13-23
|
29
|
23-26
|
35
|
28-43
|
36
|
26-48
|
|
Spread to Seminal Vesicles
|
2
|
1-5
|
5
|
1-9
|
6
|
2-12
|
5
|
1-13
|
|
Spread to Lymph Nodes
|
1
|
0-2
|
2
|
0-5
|
4
|
0-10
|
6
|
0-18
|
|
4+3=7
|
Confined
to Prostate
|
71
|
62-79
|
53
|
43-63
|
43
|
33-54
|
39
|
26-54
|
| |
Spread to Prostate Capsule
|
25
|
18-34
|
40
|
30-49
|
45
|
35-56
|
45
|
32-59
|
| |
Spread to Seminal Vesicles
|
2
|
1-5
|
4
|
1-9
|
5
|
1-11
|
5
|
1-12
|
| |
Spread to Lymph Nodes
|
1
|
0-4
|
3
|
0-8
|
6
|
0-14
|
9
|
0-26
|
|
8-10
|
Confined
to Prostate
|
66
|
54-76
|
47
|
35-59
|
37
|
26-49
|
34
|
21-48
|
|
Spread to Prostate Capsule
|
28
|
20-38
|
42
|
32-53
|
46
|
35-58
|
47
|
33-61
|
|
Spread to Seminal Vesicles
|
4
|
1-10
|
7
|
2-16
|
9
|
2-20
|
8
|
2-19
|
|
Spread to Lymph Nodes
|
1
|
0-4
|
3
|
0-9
|
6
|
0-16
|
10
|
0-27
|
